Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sangamo Therapeutics excels in 2022 trials, prioritizes innovative programs

Sangamo Therapeutics had a strong year in 2022, focusing on key programs like CAR-Treg and Fabry disease while making strategic decisions to optimize resources.
Positive trial results and FDA alignment signal progress and potential for future collaborations and advancements in treatments.
Challenges include resource reallocation, endpoint validation, and data transparency, which require careful management and strategic planning.
Overall, Sangamo's performance, strengths, and opportunities position the company well for continued growth and innovation in the biopharmaceutical sector.

Sangamo Therapeutics reports strong Q1 revenue and strategic reorganization

Sangamo Therapeutics is strategically reorganizing to focus on neurology, Fabry, and TX200 CAR-Treg programs, aiming to reduce cash burn and enhance operational efficiency.
The company's emphasis on genomic medicines for chronic pain and neurological disorders highlights its commitment to addressing significant unmet medical needs.
While facing capital constraints, Sangamo is exploring financing options and partnerships to support future growth and innovation, balancing patient benefit and safety in clinical advancements.

Sangamo Therapeutics excels in clinical progress and strategic collaborations

Sangamo Therapeutics demonstrates strong performance in clinical and preclinical programs, backed by a solid financial position and strategic collaborations. Challenges include the need for additional funding and ensuring successful trial execution. Opportunities for growth through expanding partnerships and innovative genomic engineering approaches.

Sangamo shifts focus to neurology, eyes partnerships for growth

Sangamo's strategic shift to neurology shows promise but requires navigating challenges of restructuring and resource reallocation.
The company's financial discipline and focus on operational efficiency aim to ensure self-sustainability until Q3 2024 without additional capital raises.
Progress in innovative therapies like CAR-Tregs and AAV capsid evolution positions Sangamo well for advancements in genomic medicine for neurological disorders.
Exploration of partnerships and monetization opportunities present avenues for growth and strategic advancement in Sangamo's therapeutic programs.

Sangamo Therapeutics excels in neurology advancements and financial stability

Sangamo Therapeutics made significant strides in neurology programs, financial stability, and technology advancements, positioning the company for future growth
Challenges in clinical trial navigation and funding require strategic planning, while opportunities in collaborations and partnerships offer avenues for expansion
Overall, Sangamo's focus on innovation, cost efficiency, and strategic collaborations bode well for its continued success in the neurology and gene therapy space

Sangamo Therapeutics reports positive trial results and lucrative collaborations

Sangamo Therapeutics showcased strong performance in their pipeline with positive trial results and progress in the Fabry disease program.
The company's collaboration agreements and innovative technologies position them well for future growth and revenue generation.
While facing challenges in manufacturing and commercialization, Sangamo has significant opportunities in advancing genomic medicines and expanding therapeutic applications.

Sangamo Therapeutics excels in Q3, secures key partnerships and milestones

Sangamo Therapeutics demonstrated strong performance in Q3 2024, with notable advancements in key programs and financial stability.
The company's strategic partnerships, licensing agreements, and regulatory progress position it well for future growth and commercial success.
While facing funding challenges and regulatory timelines, Sangamo has opportunities to expand its pipeline, address unmet medical needs, and drive innovation in the biopharmaceutical space.
Overall, Sangamo's progress in multiple programs and ongoing discussions for collaborations underscore its commitment to delivering innovative therapies to patients in need.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Pfizer

The small-cap won't receive an expected payout in the first quarter, creating a cash overhang.

Sangamo Therapeutics' stock falls the most in 16 years after Pfizer ends Hemophilia pact

Sangamo Therapeutics (SGMO) shares cratered more than 50% Tuesday, a day after the biopharma firm announced that Pfizer (PFE) had pulled out of its deal to co-develop a hemophilia drug.

Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact

On Monday, Sangamo Therapeutics, Inc. SGMO regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc PFE.

Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday.

Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Sangamo stock crashes 60.4% as partner Pfizer decides to end collaboration for hemophilia A candidate, giroctocogene fitelparvovec.

SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate

Shares in Sangamo Therapeutics dropped 50% premarket after Pfizer Inc (NYSE:PFE, ETR:PFE) ended its collaboration on a gene therapy for haemophilia The drug, giroctocogene fitelparvovec, met its target in a late-stage trial, with Pfizer previously expected to seek regulatory approval in 2025. “We were extremely surprised and very disappointed,” said Sangamo's CEO, Sandy Macrae.

Sangamo Therapeutics down 50% premarket on Pfizer blow

Sangamo Therapeutics said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer terminated the agreement.

Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER'S DECISION TO CEASE DEVELOPMENT.

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene Fitelparvovec

Sangamo Therapeutics, Inc. received IND clearance to initiate a phase 1/2 study for ST-503 targeting idiopathic small fiber neuropathy, a type of chronic neuropathic pain condition. SGMO entered a deal with Astellas, allowing the use of its STAC-BBB capsid for the development of up to 5 neurological disorders; a $20 million upfront payment & $1.3 billion milestone payments. The global Neuropathic Pain market size is projected to grow to $14.05 billion by 2032.

Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development

- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales - TOKYO and RICHMOND, Calif. , Dec. 19, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing Astellas to leverage Sangamo's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates.

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY.

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript

Sangamo Therapeutics (SGMO) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.34 per share a year ago.

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results.

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES THIRD QUARTER 2024 CONFERENCE CALL AND WEBCAST.

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Positive Type B meeting held with FDA, whereby U.S. agency stated that the phase 1/2 STAAR study using isaralgagene civaparvovec targeting Fabry Disease patients would be enough for Accelerated Approval. The global Fabry Disease treatment market size is expected to be worth $3.34 billion by 2030. Data from the phase 1/2 STARR study, using isaralgagene civaparvovec targeting patients with Fabry Disease, is expected in the first half of 2025.

Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025.

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors.

Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check.

AN2 Therapeutics Inc

InflaRx

Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky.

3 Penny Stocks To Buy With Just $750

Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants Nicole Germino - Truist Securities Gena Wang - Barclays Yanan Zhu - Wells Fargo Maury Raycroft - Jefferies Lisa Walter - RBC Operator Good afternoon, and welcome to the Sangamo Therapeutics Second Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded.

Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago.

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results.

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Sangamo Therapeutics (NASDAQ: SGMO ) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license agreement Genentech for the development of intravenously administered genomic medicines to treat certain neurodegenerative diseases.

Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Announces Epigenetic Regulation and Capsid Delivery Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases.

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES SECOND QUARTER 2024 CONFERENCE CALL AND WEBCAST.

News for Sangamo Therapeutics Stock (SGMO)